Amit M. Oza
YOU?
Author Swipe
View article: Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis
Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis Open
Background Clinical trials (CTs) are essential for expanding treatment options across hematologic malignancies (HM) and providing access to novel treatments. However, older adults with HM are often underrepresented in CTs, and a national‐l…
View article: Elucidating divergent biology in uterine carcinosarcoma
Elucidating divergent biology in uterine carcinosarcoma Open
By elucidating the complex interplay between the epithelial and mesenchymal components, this study enhances our understanding of UCS and informs the development of novel therapeutic strategies targeting both genomic alterations and the TME.
View article: Figure S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S3 shows that p53 loss diminishes H3K9me3 at transcriptionally upregulated repetitive elements
View article: Data from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Data from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Epigenetic therapies facilitate transcription of immunogenic repetitive elements that cull cancer cells through “viral mimicry” responses. Paradoxically, cancer-initiating events also facilitate transcription of repetitive elements. Contri…
View article: Table S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Table S3: Antibodies used in this study
View article: Figure S7 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S7 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S7 that shows the impact of viral mimicry conditioning on therapeutic approaches
View article: Figure S6 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S6 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S6 that shows Acquisition of viral mimicry tolerance affects antitumor adaptive immune responses
View article: Figure S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S2 shows that Trp53 mutation facilitates transcriptional dysregulation of retrotransposons in murine oviductal epithelial cells and ovarian surface epithelial cells.
View article: Table S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Table S4: Primer sequences used in this study
View article: Table S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Table S2: Guide RNAs used for CRISPR gene editing in this study
View article: Figure S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S4 shows that p53 loss increases cytosolic accumulation of RNA:DNA and dsRNA
View article: Figure S5 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S5 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S5 that shows Viral mimicry conditioning diminishes Type I IFN
View article: Table S1 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S1 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Table S1: Patient cohort characteristics
View article: Figure S1 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S1 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion Open
Figure S1 Shows that TP53 mutation facilitates transcriptional dysregulation of retrotransposons in STICs and human fallopian tube secretory epithelial cells
View article: Maveropepimut-S, Pembrolizumab and Low-dose Cyclophosphamide in Patients with Metastatic Ovarian Cancer: Final Results from Phase 1/2 PESCO trial
Maveropepimut-S, Pembrolizumab and Low-dose Cyclophosphamide in Patients with Metastatic Ovarian Cancer: Final Results from Phase 1/2 PESCO trial Open
Background: Epithelial ovarian cancer (EOC) is characterized by a pattern of relapse and progression through successive recurrences, with increasing chemotherapy resistance. This highlights an urgent need for novel treatment strategies. Su…
View article: Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S2: Figure 7: Mean ± SD concentration versus time profiles of AR (ADC), total antibody, DM4, and DM4-Me after administration of AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
View article: Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
trial protocol
View article: Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Purpose:Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assesse…
View article: Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Representativeness of Study Participants
View article: Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
: Pharmacokinetic parameters of AR after administration of 2.2 mg/kg AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
View article: Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Treatment-related AEs (Any grade)
View article: Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S1: Study Scheme
View article: Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S3. Relationship between anetumab ravtansine AUC0-inf (A) and DM4 AUC0-168h (B) and best antitumor response.
View article: Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Purpose: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assess…
View article: Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a 6-continent survey
Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a 6-continent survey Open
There is a need for better strategies to improve diversity in clinical trials, focusing on overcoming language barriers and eligibility constraints.
View article: TriSpectraKAN: A novel approach for COPD Detection via Lung Sound Analysis
TriSpectraKAN: A novel approach for COPD Detection via Lung Sound Analysis Open
This study aims to create an automated, accessible, andcost-effective diagnostic tool for Chronic Obstructive Pulmonary Disease(COPD). Traditional diagnostic methods are expensive, time-consuming,and require specialized equipment. The prop…